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Abstract 18 
Hepatitis C Virus (HCV) affects about 170 million people worldwide. The current treatment has 19 
a high cost and variable response rates according to the virus genotype. Acridones, a group of 20 
compounds extracted from natural sources, showed potential antiviral actions against HCV. 21 
Thus, this study aimed to evaluate the effect of a panel of 14 synthetic acridones on the HCV life 22 
cycle. The compounds were screened using an Huh7.5 cell line stably harboring the HCV 23 
genotype 2a subgenomic replicon SGR-JFH1-FEO. Cells were incubated in the presence or 24 
absence of compounds for 72 hours and cell viability and replication levels were assessed by 25 
MTT and luciferase assays, respectively. The acridone Fac4 at 5 µM inhibited approximately 90 26 
% of HCV replication with 100 % of cell viability. The effects of Fac4 on virus replication, entry 27 
and release steps were evaluated in Huh7.5 cells infected with the JFH-1 isolate of HCV 28 
(HCVcc). Fac4 inhibited approximately 70 % of JFH-1 replication, while no effect was observed 29 
on virus entry. The antiviral activity of Fac4 was also observed on the viral release, with almost 30 
80% of inhibition. No inhibitory effect was observed against genotype 3 replication. Fac4 31 
demonstrated 40% of intercalation into dsRNA, however did not inhibit T7 polymerase activity, 32 
as well as translation by IRES interaction. Although its mode of action is partly understood, the 33 
Fac4 presents significant inhibition of Hepatitis C virus replication and can therefore be 34 
considered as a candidate for the development of a future anti-HCV treatment. 35 
 36 
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Introduction 40 
Hepatitis C virus (HCV) is a global health problem, widely distributed, that affects 41 
approximately 170 million people around the world (Alter & Seeff, 2000; Houghton, 2009). 42 
HCV, the causative agent of this disease, is a single stranded RNA positive genome virus that 43 
belongs to Flaviviridae family and is classified as a group IV virus, according to Baltimore 44 
classification (Baltimore, 1971; Penin et al., 2004):LWKDJHQRPHRINEIODQNHGE\¶DQG45 
¶ XQWUDQVODWHG UHJLRQV WKH RSHQ UHDGLQJ IUDPH FRGHV IRU D SRO\SURWHLQ RI DERXW  DPLQR46 
acids (Suzuki et al., 2007). Viral and host proteases cleave this polyprotein, producing 3 47 
structural proteins (Core, E1 and E2) and 7 non-structural proteins (p7, NS2, NS3, NS4A, NS4B, 48 
NS5A and NS5B) (Dustin & Rice, 2007; Lindenbach & Rice, 2005; Penin et al., 2004).   49 
Due to the high genetic variability, mainly derived from the lack of proof-reading activity of 50 
RNA-dependent RNA polymerase NS5B and high replication rate during infection (Argentini et 51 
al., 2009), HCV is divided into genotypes (1 to 7) and subtypes (classified by lowercase letters ± 52 
a, b, c) (Murphy et al., 2007; Simmonds et al., 2005; Simmonds et al., 1993). Furthermore, in an 53 
infected individual it circulates as a pool of variants genetically related, named quasispecies 54 
which provides a favorable environment for the emergence of mutations resulting in drugs 55 
resistance  (Cristina et al., 2007; Davis, 1999; Martell et al., 1992; Pawlotsky, 2006). Therefore, 56 
the quasispecies nature of HCV has a direct impact in the effectiveness of treatment with usual 57 
medications, as well as the development of new antivirals (Le Guillou-Guillemette et al., 2007). 58 
With the current development of the Direct Acting Antivirals (DAAs) such as protease, 59 
polymerase and NS5A inhibitors, the most effective treatment is the administration of DAAs 60 
with or without pegIFN-ĮDQGULEDYLULQ(Gao et al., 2010; Lawitz et al., 2013; Rosenquist et al., 61 
2014). Treatment strategy is designed based on virological, clinical and liver pathology aspects.  62 
The SVR is variable and dependent on virus genotype and the stage of liver disease. Jacobson et 63 
  
al. evaluated two groups of patients during 12 weeks of treatment with sofosbuvir and ribavirin. 64 
The group infected with HCV genotype 2 presented around 90% of SVR, while patients infected 65 
with genotype 3 showed only 61% of SVR (Jacobson et al., 2013).  This reduced efficacy in 66 
genotype 3, coupled with potential side effects such as anemia, autoimmune disorders, diarrhea, 67 
rash, retinopathy and weight loss, as well as the elevated cost, means that additional therapeutic 68 
options are still required (Munir et al., 2010).  69 
Alkaloids is a central class of natural products, which have been extensively used as modern 70 
drug prototypes and drugs (Newman & Cragg, 2016). Among these, acridones are planar 71 
compounds isolated from Rutaceae plants, and exhibited several bioactivities, including; 72 
antimicrobial, cytotoxic, algicidal, moluscicidal, anti-allergic and antidiabetic (Michael, 2008). 73 
Also, synthetic compounds containing acridone framework have demonstrated correlated 74 
bioactivities to their natural analogues (Alwan et al., 2015). The antiviral action of acridones is 75 
well known in literature against HSV-2 and CMV replication and inhibiting HIV-1 transcription 76 
(Fujiwara et al., 1999; Turpin et al., 1998; Yamamoto et al., 1989). Recent studies revealed the 77 
potential anti-HCV effect of acridone derivatives as NS3 helicase inhibitor and as dsRNA 78 
intercalant, inhibiting viral replication (Stankiewicz-Drogon et al., 2010; Stankiewicz-Drogon et 79 
al., 2008). 80 
Considering the high cost and several side effects of current HCV treatment, the development of 81 
new drugs against the virus remains an important subject of research. The aim of this study was 82 
to investigate the effects of synthetic acridone Fac4 on HCV life cycle by the use of in vitro 83 
approaches.  84 
  85 
  
Results 86 
Inhibitory activity of Fac4 on JFH1 replication. 87 
We performed a screening with a panel of 14 synthetic acridones to select those with potential 88 
antiviral activity on HCV replication. Huh 7.5 cells stably harboring SGR-Feo-JFH-1 were 89 
treated with compounds at 50, 10, 2 and 0.4 µM. After 72 h incubation, luciferase and MTT 90 
assays were performed in parallel to evaluate the replication inhibition and cell viability under 91 
the treatment with the compounds, respectively. Among tested acridones, Fac4 presented a 92 
potential activity against HCV replication. This acridone at 10 µM presented cell viability of 85 93 
% with inhibition of viral replication by approximately 89 %. Fac4 inhibited replication in a 94 
concentration-dependent manner (data not shown) with EC50 of 1.33uM and SI (CC50/EC50) of 95 
42.14. To find the useful selectivity index (favorable ratio of cytotoxicity to antiviral potency), a 96 
screening was performed with Fac4 at concentrations from 1 to 10 µM. We observed that Fac4 at 97 
5 µM inhibited 92 % of HCV replication (Fig. 2a). Therefore, this concentration was selected to 98 
the further experiments.   99 
Thus, we evaluate the effects of Fac4 on the HCV replication in the context of full length virus. 100 
Huh 7.5 cells were infected with JFH1 HCVcc and after 4h, viral supernatant was removed and 101 
cells were treated with Fac4 for 72 hours. Cells were fixed, stained and titrated. Fac4 inhibited 102 
approximately 70 % of HCV replication (Fig. 2b), corroborating the potential antiviral activity 103 
against HCV observed in the preliminary replicon assays. As expected, protein expression levels 104 
were also significantly reduced in the presence of Fac4 since NS5A was undetectable when cells 105 
were treated with Fac4 (Fig. 2b). 106 
Once Fac4 presented a potential inhibition of HCV genotype 2a JFH1 replication, we decided to 107 
test if these results are genotype-specific. For that, Huh 7.5 cells stably harboring the genotype 3 108 
  
subgenomic replicon S52/SG-Feo were treated with Fac4 at 5µM and replication levels were 109 
analyzed by luciferase assay. No inhibition of genotype 3 replication was observed (Fig. 2c). 110 
Fac4 as a dsRNA intercalator.  111 
To further investigate the antiviral mode of action of Fac4, we analyzed the capacity of this 112 
compound to intercalate into GV51$8VLQJWKH¶875UHJLRQRI-)++&9DVDWHPSODWHZH113 
produced an amplicon flanked by T7 promoter that was used for in vitro transcription, 114 
synthesizing a dsRNA molecule of 273 bp.  This dsRNA was incubated with Fac4 at 5µM or the 115 
controls (DMSO 0.1% and Doxorubicin at 100µM) and was analyzed by a migration retardation 116 
assay. Fac4 presented 40% of dsRNA intercalation when compared to the DMSO negative 117 
control, quantified by densitometry (Fig. 3a). Notice that the sample treated with Doxorrubicin 118 
(positive control of intercalation) does not appear in the image, reasserting the observed result. 119 
T7 RNA polymerase inhibition assay 120 
In order to investigate if Fac4 has an inhibitory effect on the polymerase activity, we performed 121 
an in vitro transcription of HCV JFH-1 RNA in the presence of Fac4. For that, T7 RNA 122 
polymerase was used, which as stated earlier, is similar to NS5B viral polymerase(Stankiewicz-123 
Drogon et al., 2010; Stankiewicz-Drogon et al., 2008). Fac4 did not present any activity on T7 124 
enzymatic process since no difference was observed when compared to the control (Fig. 3b). 125 
The results suggest it is unlikely that Fac4 has an effect on NS5B, however this possibility 126 
cannot be completely discarded. 127 
 128 
Fac4 and IRES-mediated translation. 129 
 130 
  
An IRES-mediated translation assay was carried out to investigate a possible interaction between 131 
Fac4 and IRES and therefore to evaluate if the inhibition of viral replication is related to the 132 
IRES-mediated translation. Cells electroporated with SGR-Feo-JFH-1 or SGR-luc-JFH1/GND 133 
were immediately incubated with Fac4 or controls and RNA replication was estimated after 4h 134 
by luciferase expression analysis. Fac4 did not influence the viral RNA translation, since 135 
luciferase values of both wild type replicon and the GND replication defective replicon at 4h 136 
were not reduced, demonstrating the input RNA was translated in to the cells (Fig. 3c). 137 
Fac4 does not block virus entry.  138 
To evaluate whether Fac4 possess antiviral activity on HCV entry, Huh 7.5 cells were infected 139 
with JFH1 virus in the presence or absence of Fac4 for 4 h. Viral inoculum was replaced by fresh 140 
media and intracellular virus was quantified72 h.p.i.. No blockage of viral entry was observed 141 
(Fig. 4). 142 
Fac4 inhibits HCV release 143 
 144 
Since Fac4 has antiviral activity against HCV replication but does not act during viral entry 145 
process, we decided to analyze the release step. We observed that intracellular RNA in Fac4-146 
treated cells displayed similar values as the non-treated cells. However, a pronounced effect on 147 
virus release (extracellular RNA) is observed since there was 80% of difference in the amount of 148 
intra and extracellular HCV RNA (Fig. 5). 149 
  
Discussion 150 
The antiviral effect of acridones has been described in literature and the activity spectrum of this 151 
class of alkaloids varies depending on the type of viral genome (double-stranded DNA genome 152 
or RNA viruses) (Sepulveda et al., 2013). Some acridones from Rutaceae plants showed great 153 
antiviral activity against viruses with DNA genomes like herpes simplex virus serotypes 1 and 2 154 
(HSV-1 and HSV-2), human cytomegalovirus (HCMV) and Epstein-Barr virus (Chansriniyom et 155 
al., 2009; Itoigawa et al., 2003; Takemura et al., 1995; Yamamoto et al., 1989). For RNA 156 
viruses, acridones presented activity against HIV-1, bovine viral diarrhea virus (BVDV), all 157 
serotypes of dengue virus (DENV) and HCV, the last three belonging to the Flaviviridae family 158 
(Fujiwara et al., 1999; Houe, 2003; Mazzucco et al., 2015; Raney et al., 2010; Sepulveda et al., 159 
2008; Stankiewicz-Drogon et al., 2010; Stankiewicz-Drogon et al., 2008; Tabarrini et al., 2006; 160 
Turpin et al., 1998).   161 
Our results showed that Fac4 inhibited up to 92% of HCV replication in the context of either the 162 
subgenomic replicon or full length JFH1 HCVcc. Also, NS5A viral protein expression could not 163 
be detected after the treatment with this compound. Despite its considerable effect on HCV 164 
genotype 2, inhibition was not observed on HCV genotype 3 replication. So far, all NS3 protease 165 
inhibitors available have also no effect on HCV genotype 3 (Gentile et al., 2014; Hayashi et al., 166 
2014; Rosenquist et al., 2014; Summa et al., 2012). Altogether, the hypothesis that Fac4 is 167 
interfering with NS3 protease is strengthened. However, to determine whether Fac4 is inhibiting 168 
NS3 protease activity further functional studies are needed. 169 
Despite the observed inhibition of replication, Fac4 had no activity on HCV viral entry. This 170 
could be explained by the way acridones usually act against virus infection. Some authors argue 171 
that their nucleic acid intercalation ability and interaction with viral enzymes are the main 172 
mechanisms by which these compounds act (Adams, 2002; Stankiewicz-Drogon et al., 2010; 173 
  
Stankiewicz-Drogon et al., 2008). For HCV, data presented by Stankiewicz-Drogon and co-174 
workers (Stankiewicz-Drogon et al., 2010; Stankiewicz-Drogon et al., 2008) reinforces this 175 
assumption. Acridones showed inhibition of NS3 helicase, T7 RNA polymerase (topology and 176 
function similar to HCV NS5B) and strong double-stranded RNA intercalation property. All 177 
these elements are involved in the replication step.  178 
It is not clear yet if there is a combination of the reported effects of acridones on the inhibition of 179 
replication. Some acridones described in the literature present dsRNA intercalation property, 180 
others show inhibition of NS3 helicase and NS5B polymerase, and some present both effects 181 
(Manfroni et al., 2009; Stankiewicz-Drogon et al., 2010). However, all these studies performed 182 
in isolated assays, evaluating inhibition of enzymatic activity or dsRNA intercalation 183 
individually. According to our results, Fac4 presented the ability to partially intercalate in 184 
dsRNA, however it does not inhibit T7 RNA polymerase. As reported before (Stankiewicz-185 
Drogon et al., 2010; Stankiewicz-Drogon et al., 2008), it is presumed that HCV replication 186 
cannot be inhibited by dsRNA intercalation alone, and probably it is due to a combined effect 187 
between different modes of action. Therefore, replication inhibition by Fac4 may be somewhat 188 
related to dsRNA intercalation, which is a replication intermediate. However it is likely that 189 
other mode of action, such as enzymatic inhibition is also involved (Stankiewicz-Drogon et al., 190 
2010; Stankiewicz-Drogon et al., 2008; Tabarrini et al., 2006). Another possible explanation for 191 
the antiviral activity of Fac4 is the targeting of cellular components. Some acridone derivatives, 192 
such as cycloferon (CMA), are described as compounds which can induce the interferon pathway 193 
(Kovalenko et al., 2000; Storch et al., 1986). However, these assumptions remain to be 194 
investigated. 195 
 196 
The result observed in viral release assay reinforces the antiviral activity of Fac4. The compound 197 
presented almost 80% of inhibition in HCV release step (extracellular RNA level). This assay is 198 
  
performed 24h after treatment and to explain the lack of effect in the intracellular levels, we 199 
performed a replication assay 24h after treatment, where luciferase levels were similar to the 200 
control (data not shown). The inhibition of replication was observed 72h after treatment. These 201 
results could indicate that, after 24h, Fac4 has not yet influenced HCV replication in a significant 202 
way, however some interaction between the acridone and the viral RNA is occurring in a way 203 
that prevents the release of new viral particles. 204 
Herein, we reported the acridone Fac4 as a potent inhibitor of in vitro HCV genotype 2 205 
replication and release. This inhibition was correlated to dsRNA intercalation possibly associated 206 
with other mechanisms. Although the mode of action of this compound is partly understood, this 207 
drug is candidate for further studies as a future anti-HCV agent.   208 
209 
  
Materials and Methods 210 
 211 
Synthesis and Identification of Fac4 212 
The trihydroxylated acridone Fac4 was synthesized as the protocol previously described by 213 
Herath and co-authors (Herath et al., 2004). A mixture of phloroglucinol (19 mmol), 2-amino-3-214 
hydroxybenzoic acid (13 mmol), and para-toluenosulphonic acid (0.5 mmol) in 1-hexanol (65 215 
mL) was refluxed for 8 h. The heterogenous mixture was stirred with cold hexane. The crude 216 
pale yellow product was recrystallized from mixture of ethanol and acetone (1:1), yielding 43% 217 
of Fac4. The structure of Fac4 was elucidated by analysis of Nuclear Magnetic Resonance 218 
(NMR) spectra, including NMR 1H and 13C NMR. Chemical shifts (į) were expressed in ppm. 219 
Coupling constants (J) were expressed in Hz, and splitting patterns are described as follows; s = 220 
singlet, d = doublet and dd = double of doublets (Fig. 1a).  221 
1,3,5-trihydroxy-9(10H)-acridinone. 1H NMR (11.7 T;DMSO-d6): 5.98 (d; 2.0; H-2), 6.67 (d; 222 
2.0; H-4), 7.14 (dd; 2.5 and 7.5; H-6), 7.05 (dd; 8.0 and 7.5; H-7), 7.61 (dd; 2.5 and 8.0; H-8), 223 
11.1 (s; H-10); 14.3 (s; 1-OH), 10.3 (s; 3-OH), 10.6 (s; 5-OH). 13C NMR (11.7 T; DMSO-d6): 224 
163.8 (C-1), 95.6 (C-2), 163.4 (C-3), 91.9 (C-4), 145.4 (C-5), 115.9 (C-6), 120.9 (C-7), 114.8 225 
(C-8), 180.0 (C-9), 143.2 (C-4a), 131.4 (C-5a), 119.8 (C-8a), and 103.4 (C-9a).      226 
Virus Constructs 227 
The HCV subgenomic replicon SGR-Feo-JFH-1 was used in initial screening to evaluate the 228 
effect of the compounds on virus replication (Wyles et al., 2009). This construct carries the 229 
phosphotransferase luciferase-neomycin fusion gene. To evaluate if the inhibitory effect was 230 
genotype-specific, the genotype 3 subgenomic replicon S52/SG-Feo was used (Saeed et al., 231 
  
2012). For replication, entry, release and for virus protein expression analysis, infection assays 232 
were carried out with full length HCV JFH-1 isolate (Wakita et al., 2005) (Fig. 1b).   233 
Cell culture 234 
Huh 7.5 cells and Huh 7.5 stably harboring subgenomic replicons SGR-Feo-JFH-1 and S52/SG-235 
Feo ZHUH FXOWXUHG LQ 'XOEHFFR¶V PRGLILHG (DJOHV Medium (DMEM; Sigma-Aldrich) 236 
supplemented with 100 IU penicillin mL-1, 100 µg streptomycin mL-1, 0.5 mg mL-1 of geneticin 237 
(G418), 10% fetal calf serum and incubated at 37 ºC and 5% CO2. 238 
Experimental delineation for initial screening 239 
An initial screening was performed to test a panel of acridones for their antiviral activity on 240 
HCV replication. Compounds were dissolved in DMSO (Dimethyl sulfoxide ± Sigma Aldrich) 241 
and diluted in media immediately prior the assay. The final concentration of DMSO in all assays 242 
was 0.1 %. For each compound, cytotoxicity and replication assays were performed. Huh 7.5 243 
cells harboring SGR-JFH1-FEO were seeded in 96 well plates at the density of 3 × 103 and 244 
incubated in the presence or absence of compounds for 72h. Cyclosporine A at 1 µM was used as 245 
a control for replication inhibition and DMSO 0.1% as non-treated control. Assays were 246 
performed in triplicates and a minimum of three times. Four concentrations were tested (50, 10, 247 
2 and 0.4 µM).  248 
Replication assay for subgenomic replicons 249 
After treatment, cells were harvested with Passive Lysis Buffer (PLB) (Promega). Replication 250 
levels were quantified by measuring luciferase activity with the Luciferase Assay System 251 
(Promega) in a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). Data 252 
was normalized by DMSO control. 253 
  
Cytotoxicity assay 254 
After 72h of treatment, the media was removed, cells were incubated at 37ºC with DMEM 255 
containing MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma-256 
Aldrich) at 1 mg mL-1. After 30 minutes, MTT was removed and 100 µL of DMSO was added to 257 
solubilize formazan crystals. Cell viability was determined by measuring optical density in the 258 
microplate reader. Compounds were classified as non-toxic, when cells presented viability over 259 
80%. 260 
Effective Concentration 50% (EC50) 261 
The effective concentration 50% (EC50) was calculated using Prism (GraphPad) and cytotoxicity 262 
assays were carried out in parallel to determine the cytotoxic concentration 50% (CC50) using a 263 
MTT-based system as described in cytotoxic assay section. The values of CC50 and EC50 were 264 
used to calculate the selectivity index (SI = CC50/EC50), which suggests the potential antiviral 265 
activity of the compounds. 266 
Viral production 267 
HCV JFH1 RNA was elHFWURSRUDWHGLQWR+XKFHOOVDW9)DQGUHVLVWDQFHXVLQJ268 
a 4 mm cuvette in the Gene PulserXcell Electroporation System (Bio-Rad, Philadelphia, PA, 269 
USA). Fifteen days after electroporation supernatant was collected, concentrated with PEG 8000 270 
(Polyethylene glycol) (Sigma-Aldrich) and titrated by focus formation unit assay. 271 
JFH1 Replication assay  272 
Huh 7.5 cells were seeded in 96 well plates the day before the assay. Cells were infected with 273 
JFH1 virus (MOI of 0.2) for 4 h at 37ºC and 5% CO2, washed extensively to remove virus and 274 
subsequently treated with Fac4 (5 µM). After 72 h, cells were fixed with 4% PFA (Synth) and 275 
  
stained for NS5A using sheep anti-NS5A (Macdonald et al., 2003) and Alexa Fluor anti-sheep 276 
594 secondary antibody. Virus titers were obtained by focus formation unit analysis. Data was 277 
normalized by DMSO control and cyclosporine at 1µM was used as a control of inhibition of 278 
replication. 279 
Viral entry 280 
For virus entry experiments, infectious supernatant and Fac4 were added simultaneously to Huh-281 
7.5 cells. Four hours post-infection (h.p.i), supernatant was removed, washed extensively and 282 
replaced with fresh medium. Cells were incubated for 48 hours. DMSO and (±)-epigallocatechin 283 
gallate (EGCG, Sigma-Aldrich) were used as negative and positive controls, respectively. Cells 284 
were fixed and intra cellular virus was titrated. 285 
Viral release analysis  286 
To analyze Fac4 effect on HCV secretion, 2 × 105 JFH-1 infected cells were seeded 48 h before 287 
treatment. Then, the medium was replaced by fresh medium supplemented with Fac4 was added 288 
at 5 µM or controls as previously described (Nahmias et al., 2008). DMSO 0.1 % was used as 289 
non-treated control and nDULQJHQLQ 15 DW  ȝ0 ZDV used as control of HCV secretion 290 
inhibition (Nahmias et al., 2008). After 24 h of incubation, RNA was extracted from the 291 
supernatant and from the cells using TRIzol reagent (Life Technologies), and cDNA was 292 
synthesized with High-Capacity cDNA Archive (Applied Biosystems). HCV expression analysis 293 
was performed by TaqMan Universal PCR Master Mix no AmpErase UNG (Applied 294 
Biosystems) detecting the amplification of the HCV ¶875 UHJLRQ (Forward: 295 
CGGGAGAGCCATAGTGG; Reverse: AGTACCAACAAGGCCTTTCG). The samples quality 296 
and normalization of levels of expression were obtained by amplification of the endogenous gene 297 
GAPDH. JFH1 release inhibition was calculated as a percentage of negative control.  298 
 299 
  
Western blotting 300 
Cells were lysed using Cell Lytic (Sigma-Aldrich) and protein was quantified with PierceTM 301 
BCA Protein Assay Kit (Thermo Scientific), following the manufacturers protocol. 302 
Approximately 10 µg of protein was resolved in SDS-PAGE electrophoresis, transferred to a 303 
nitrocellulose membrane and blocked with nonfat milk 10% in TBS-T solution. The membrane 304 
was probed at 4ºC with sheep Anti-NS5A antibody overnight (Macdonald et al., 2003) and then 305 
with secondary Anti-sheep IgG antibody conjugated with HRP (Sigma-Aldrich) at room 306 
temperature for 1h. The membrane was washed in TBS-T, exposed to ECL (Enhanced 307 
Chemiluminescent) and chemiluminescence was captured by ChemiDoc equipment (Bio-Rad, 308 
Philadelphia, PA, USA). After stripping, membrane was probed for 1h at room temperature with 309 
Anti-GAPDH antibody conjugated with HRP. After exposure to ECL, the blotting was analyzed 310 
in ChemiDoc.  311 
dsRNA intercalation assay 312 
To analyze the ability of Fac4 to intercalate in dsRNA, a migration retardation assay was 313 
performed based on the previously described protocol of Krawczyk et al.(Krawczyk et al., 314 
2009)7KH+&9-)+¶XQWUDQVODWHGUHJLRQ875DFFHVVLRQQRAB047639) was amplified 315 
by PCR using primers flanked by a T7 promoter site 316 
(Forward:TAATACGACTCACTATAGGGGGCACACACTAGGTACA; Reverse: 317 
TAATACGACTCACTATAGGGACATGATCTGCAGAGAG; T7 promoter regions are 318 
underlined). The reaction product (273 bp) was purified by ZymocleanTM Gel DNA recovery Kit 319 
(Zymo Research) and used for in vitro transcription by the T7 Ribomax Express kit (large scale 320 
RNA production system) (Promega). The dsRNA molecule was obtained by complementary 321 
annealing and incubated at 15 nM with Fac4 (5µM) for 45 min, and analyzed in 1% agarose 1X 322 
TAE gel stained with ethidium bromide. Since an intercalating compound competes with 323 
  
ethidium bromide, the intercalation of dsRNA is confirmed when the band of the treated sample 324 
is not visualized in the gel. Doxorubicin (100 µM) was used as positive control of intercalation.  325 
T7 RNA polymerase inhibition assay 326 
The T7 polymerase presents similar topology and function to the HCV RdRp NS5B 327 
(Stankiewicz-Drogon et al., 2010; Stankiewicz-Drogon et al., 2008). In order to evaluate 328 
whether Fac4 interacts with T7 consequently inhibiting viral replication, we tested the effects of 329 
FAC4 on in vitro RNA transcription.  Five in vitro transcription reactions for JFH1 RNA were 330 
performed, using the 75LER0$;([SUHVV/DUJH6FDOH51$3URGXFWLRQ6\VWHP (Promega). 331 
The compound was tested in three different concentrations (0.5 µM, 5µM and 50µM). The 332 
experiment was set up according to manufacturer instructions apart to the addition of acridone 333 
Fac4. For controls, we performed a standard reaction for JFH1 RNA synthesis and a reaction 334 
adding only DMSO, the solvent of the compounds. Synthesized RNA was quantified and 335 
analyzed in a RNA denaturant 1 % agarose gel.  336 
IRES interaction assay 337 
Huh7.5 cells were electroporated with SGR-Feo-JFH-1or SGR-luc-JFH1/GND. Immediately 338 
after electroporation, cells were seeded in 96 well plates and incubated with Fac4 (5µM) or 339 
DMSO. Cells were harvested by lysis with PLB (Promega) 4h post-electroporation and HCV 340 
RNA replication/translation was quantified by measuring luciferase activity using the Luciferase 341 
Assay System (Promega). 342 
Data analysis 343 
Cytotoxicity, subgenomic replicon and complete viral genome (JFH1) assays were performed in 344 
triplicate and a minimum of three times. All data originated from these assays were evaluated 345 
  
using software GraphPad Prism 5 (GraphPad Software, San Diego - CA, USA). Average and 346 
standard deviation were represented in each graph. Statistical analyses were done using ANOVA 347 
test and Dunnett's Multiple Comparison Test, considering P < 0.05 as significant. The statistical 348 
analyses from the release assay were performed by two-way ANOVA with Bonferroni¶VSRVWWHVW349 
using GraphPad Prism 5.0 software. All data was normalized by the non-treated control and 350 
multiplied by a hundred to obtain values in percentage.  351 
  352 
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Figure legends 
 
 
Figure 1. Structure of Fac4 and constructs: A) Structure of acridone Fac4; B) Subgenomic Replicon SGR-
JFH1-FEO, which express the genotype 2 non-structural viral proteins and the phosphotransferase fusion protein 
luciferase-neomycin, and JFH-1 replicon, which express all viral proteins. Subgenômic Replicon S52/SG-Feo 
express the genotype 3 non-structural viral proteins.  
Figure 2. Fac4 effect on HCV replication: A) Fac4 concentration screening, determining 5µM as working 
concentration (the lower concentration with best inhibitory effect and cell viability). B) Replication assay in Huh 
7.5 infected with JFH1 HCVcc and Western Blot for NS5A viral protein detection. C) Replication assay in Huh 
7.5 stably expressing genotype 3 subgenomic replicon S52/SG-Feo. Cyclosporin (CsA) used as positive control. 
The three asterisks represent a significant difference between control group and treated group at p< 0,001.  
  
Figure 3. Fac4 possible mechanisms of action: A) Intercalation assay, evaluating Fac4 dsRNA intercalation 
property. Doxorrubicin (Doxo) was used as positive control. B) Evaluation of Fac4 effect over T7 RNA 
polymerase activity during in vitro transcription. Above the RNA bands are the quantification values, in µg/µl. 
C) : IRES interaction assay in Huh 7.5 cells. Replication rate 4h after electroporations. Subgenomic replicon 
SGR-JFH1-FEO (SGR); Defective mutated subgenomic replicon SGR-luc-JFH1/GND (GND);  
Figure 4. Fac4 effect on HCV entry step: Entry assay in Huh 7.5 infected with JFH1 HCVcc. EGCG ((-)-
epigallocatechin gallate ± positive control).  
Figure 5. Fac4 effect on HCV release step9LUDOUHOHDVHDVVD\EDVHGRQ+&9¶875T3&5&HOOV+XK
JFH1-infected were treated with FAC-DORQJK'062ZDVXVHGDVQHJDWLYHFRQWURODQG1DULQJHULQȝ0
(NR) used like positive control for release inhibition. The bars present the triplicate of two independent assays. 
The three asterisks represent a significant difference between control group and treated group at p< 0,001. 
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